Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Tuesday

Tyra Biosciences (NASDAQ:TYRA) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Tyra Biosciences Stock Down 7.1 %

Shares of NASDAQ TYRA opened at $10.16 on Tuesday. Tyra Biosciences has a 52 week low of $10.02 and a 52 week high of $29.60. The firm’s fifty day moving average is $13.90 and its 200 day moving average is $17.46. The company has a market cap of $514.13 million, a price-to-earnings ratio of -6.31 and a beta of 1.09.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Tuesday, February 18th. UBS Group assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $30.50.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the transaction, the director now directly owns 443,885 shares in the company, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 21,998 shares of company stock valued at $344,818 in the last three months. 15.40% of the stock is currently owned by company insiders.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.